The following content discusses the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by the FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
RenovoRx is evaluating the use of TAMP with gemcitabine as a combination product (known as intra-arterial gemcitabine) for the treatment of locally advanced pancreatic cancer (LAPC), including in the ongoing Phase III TIGeR-PaC trial, under a U.S. Investigational New Drug Application. Ongoing clinical studies continue to evaluate safety and clinical outcomes in patients with LAPC. For RenovoCath’s Indications for Use and safety information, please visit IFU.
Learn more about how hospitals are using the TAMP™ therapy platform with the RenovoCath® device in oncology management, and participant experiences in the Phase III TIGeR-PaC clinical trial.*
Chemotherapy’s a common treatment for pancreatic cancer. However, a clinical trial underway at UT Southwestern Medical Center is using an innovative approach to better target the cancer with added benefit for late-stage patients.